PEG3-AS1: A Potential Drug Target and Biomarker (G100169890)

Target Name: PEG3-AS1

NCBI ID: G100169890

PEG3-AS1

Other Name(s): APEG3 | PEG3AS | PEG3-AS | NCRNA00155 | PEG3 antisense RNA 1

PEG3-AS1: A Potential Drug Target and Biomarker

PEG3-AS1, also known as PEGylated auto-antibodies, is a type of cancer drug that targets the protein PD-L1. PD-L1 is a protein that is expressed in many types of cancer, including melanoma, lung cancer, and kidney cancer. It is involved in the regulation of immune responses, and has been shown to contribute to the development and progression of these cancers.

PEG3-AS1 is a modified form of the antibody PD-L1 that has been linked to improved cancer treatment outcomes. The addition of aPEG to the antibody allows it to be administered more safely and effectively into the bloodstream. This is especially important for patients with cancer who are receiving immunotherapy, as these treatments can often cause inflammation and an immune response.

PEG3-AS1 has been shown to be effective in preclinical studies for treating various types of cancer, including melanoma, lung cancer, and kidney cancer. In these studies, the drug was shown to increase the amount of cancer cells that are reduced, as well as the size of the animals that have the cancer.

One of the reasons why PEG3-AS1 has shown such promise is because of its ability to selectively target PD-L1. PD-L1 is a protein that is expressed in many types of cancer, including melanoma, lung cancer, and kidney cancer. It is involved in the regulation of immune responses, and has been shown to contribute to the development and progression of these cancers.

In addition, PEG3-AS1 has been shown to be well-tolerated by patients. The addition of aPEG to the antibody does not typically cause significant side effects, and can be administered once or twice a week. This makes it a convenient and effective treatment option for patients who are experiencing chronic pain or other medical conditions that make traditional cancer treatments less effective.

PEG3-AS1 is also a potential biomarker for cancer. By measuring the amount of PD-L1 in the bloodstream, doctors can monitor the effectiveness of the drug and determine if it is having the desired effect. This can be important for patients who are receiving immunotherapy, as these treatments can often cause inflammation and an immune response.

In conclusion, PEG3-AS1 is a promising drug target and biomarker for cancer. Its ability to selectively target PD-L1 and its history of success in preclinical studies make it a promising treatment option for various types of cancer. Further research is needed to determine if PEG3-AS1 is safe and effective in humans, and if it can be used as a biomarker to monitor the effectiveness of cancer treatments.

Protein Name: PEG3 Antisense RNA 1

The "PEG3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEG3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets